Finance

Lists
Why is AARD down २.६३%?
Dive Deeper
AARD:NASDAQ
Aardvark Therapeutics Inc
US$ १.४८
-२.६३%
(-०.०४०) 1D
नोभेम्बर १३, १३:३९:०९ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AARD...
Open
US$ १.५८
High
US$ १.७०
Low
US$ १.३९
Mkt. cap
३.२४ करोड
Avg. vol.
११.८७ लाख
Volume
२.९४ लाख
52-wk high
US$ १६.६०
52-wk low
US$ ०.९३
EPS
-US$ ३.२१
Shares outstanding
२.१९ करोड
No. of employees
२८
Open
US$ १.५८
High
US$ १.७०
Low
US$ १.३९
Mkt. cap
३.२४ करोड
Avg. vol.
११.८७ लाख
Volume
२.९४ लाख
52-wk high
US$ १६.६०
52-wk low
US$ ०.९३
EPS
-US$ ३.२१
Shares outstanding
२.१९ करोड
No. of employees
२८
News stories
From web sources and news partners
About Aardvark Therapeutics Inc
CEO-
Employees२८
Founded२०१७
Headquarters-
SectorHealth Care
Industry-
Websiteaardvarktherapeutics.com
Analyst ratings
Based on 6 analysts giving stock ratings to AARD in the past 3 months
Sell
Buy
0
Hold
4
Sell
2
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AARD in the last 3 months.
Highest
Current US$ १.४८
US$ ३.०० (+१०२.७०%)
Average
US$ २.२५ (+५२.०३%)
Lowest
US$ १.५० (+१.३५%)
Analyst
Recommendation
Action
Price target
Projected
Date
Christopher Raymond
Raymond James
Hold
Downgraded
-
-
11/04/2026
Leland Gershell
Oppenheimer
Hold
Downgraded
-
-
10/26/2026
Ram Selvaraju
H.C. Wainwright
Hold
Maintained
US$ २.००
+३५.१%
10/26/2026
Brian Abrahams
RBC Capital
Hold
Maintained
US$ २.५०
+६८.९%
10/23/2026
Michael Ulz
Morgan Stanley
Sell
Maintained
US$ ३.००
+१०२.७%
10/22/2026
Tazeen Ahmad
Bank of America Securities
Sell
Reiterated
US$ १.५०
+१.४%
10/23/2026
James Condulis
Stifel Nicolaus
Hold
Reiterated
US$ ६.००
+३०५.४%
08/13/2026
Jeet Mukherjee
BTIG
Hold
Maintained
-
-
08/12/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
08/12/2026
William Wood
B. Riley Securities
Buy
Maintained
US$ ७.००
+३७३%
05/15/2026
Tim Anderson
Bank of America Securities
Buy
Reiterated
US$ १८.००
+१,११६.२%
05/08/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
US$ ४५.००
+२,९४०.५%
03/02/2026
Last report
२०२६ अगस्ट ११
Fiscal period
Q2 2026
-US$ ०.६६ / -US$ ०.८८
+२५.११%beat
Revenue / Est. (USD)
- / ०.००
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१.३७ करोड
१.४३ करोड
१.६६ करोड
१.०५ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३९.६६ लाख
४४.०५ लाख
५८.९७ लाख
४६.२९ लाख
Operating expense
१.७७ करोड
१.८७ करोड
२.२५ करोड
१.५१ करोड
Total operating expenses
१.७७ करोड
१.८७ करोड
२.२५ करोड
१.५१ करोड
Operating income
-१.७७ करोड
-१.८७ करोड
-२.२५ करोड
-१.५१ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-१.६३ करोड
-१.७६ करोड
-२.१६ करोड
-१.४४ करोड
EBT excluding unusual items
-१.६४ करोड
-१.७६ करोड
-२.१६ करोड
-१.४४ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.६३ करोड
-१.७६ करोड
-२.१६ करोड
-१.४४ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.७५
-०.८१
-०.९९
-०.६६
Interest and investment income
१३.५१ लाख
११.२५ लाख
८.८९ लाख
६.९५ लाख
Interest expense
-
-
-
-
Net interest expenses
१३.५१ लाख
११.२५ लाख
८.८९ लाख
६.९५ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.७७ करोड
-१.८७ करोड
-२.२५ करोड
-१.५१ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू